Thymalin: Research & Evidence
Early-Stage ResearchPublished research, clinical trial data, and evidence grading for Thymalin across studied indications.
Back to Thymalin overviewResearch Summary
Thymalin has approximately 20-30 human studies, almost exclusively from Russian institutions — primarily from Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. The landmark Khavinson 2003 study (PMID: 14582133, n~200) reported a 2-fold mortality reduction in elderly subjects over 6 years. However, these studies are not randomized, double-blind, or placebo-controlled by Western standards. There are 1-3 open-label Russian RCTs with potential bias. Zero Western RCTs exist, zero active clinical trials are registered on ClinicalTrials.gov, and there is no FDA pathway identified. Thymalin is fundamentally different from Thymosin Alpha-1 — it is a bovine extract (peptide mixture), while Thymosin Alpha-1 is a synthetic single peptide with substantially more evidence.
Evidence by Indication (3 indications)
| Indication | Tier | Trials | Summary |
|---|---|---|---|
| Age-related immune decline | Tier D | 1 | Khavinson 2003 prospective cohort; no Western RCTs |
| Immunodeficiency | Tier D | 0 | Uncontrolled Russian clinical reports only |
| Longevity / anti-aging | Tier D | 0 | Long-term follow-up data from Khavinson group; methodological limitations |
Graded using our evidence tier methodology.
Citations (2 sources)
- 1. Peptide bioregulation of aging: results and prospects Study
Khavinson VK (2003), Bulletin of Experimental Biology and Medicine
- 2. Thymosin alpha 1: a comprehensive review Review
Romani L, et al. (2002), Annals of the New York Academy of Sciences